Sinew Pharma Inc. (TPEX:6634)

Sinew Pharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	0.33	6.23	0.46
Revenue Growth (YoY)	-	-	-94.73%	1248.27%	-
Cost of Revenue	-	-	0.04	1.14	0.14
Gross Profit	-	-	0.29	5.09	0.32
Selling, General & Admin	36.95	34.75	34.1	26.77	17.73
Research & Development	131.91	151.51	114.62	72.75	66.71
Operating Expenses	168.86	186.25	148.72	99.51	84.43
Operating Income	-168.86	-186.25	-148.43	-94.42	-84.11
Interest Expense	-0.41	-0.78	-0.28	-0.15	-0.27
Interest & Investment Income	16.66	16.03	8.37	2.95	2.37
Other Non Operating Income (Expenses)	2.25	0.08	0.15	0.04	0
Pretax Income	-150.37	-170.92	-140.18	-91.58	-82.01
Net Income	-150.37	-170.92	-140.18	-91.58	-82.01
Net Income to Common	-150.37	-170.92	-140.18	-91.58	-82.01
Shares Outstanding (Basic)	71	70	69	59	50
Shares Outstanding (Diluted)	71	70	69	59	50
Shares Change (YoY)	1.21%	1.68%	16.47%	19.41%	30.28%
EPS (Basic)	-2.11	-2.43	-2.02	-1.54	-1.65
EPS (Diluted)	-2.11	-2.43	-2.02	-1.54	-1.65
Free Cash Flow	-106.26	-125.26	-98.99	-59.5	-61.06
Free Cash Flow Per Share	-1.49	-1.78	-1.43	-1.00	-1.23
Gross Margin	-	-	88.41%	81.75%	70.13%
Operating Margin	-	-	-45252.44%	-1515.81%	-18204.76%
Profit Margin	-	-	-42737.81%	-1470.14%	-17751.30%
Free Cash Flow Margin	-	-	-30178.66%	-955.19%	-13217.10%
EBITDA	-144.98	-163.63	-128.29	-73.88	-64.41
D&A For EBITDA	23.88	22.62	20.13	20.55	19.7
EBIT	-168.86	-186.25	-148.43	-94.42	-84.11

Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.